Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 15/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449790 | 0.95 | ADORA2A (0.90) | ADORA2AADORA1 | |
| SCHEMBL12651831 | 0.88 | ADORA2A (0.79) | ADORA2AADORA1 | |
| Cyclopropane SCHEMBL15484598 | 0.88 | ADORA2A (0.81) | ADORA2AADORA1 | |
| Cyclohexane SCHEMBL15484591 | 0.88 | ADORA2A (0.81) | ADORA2AADORA1 | |
| SCHEMBL1449872 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL1449975 | 0.86 | ADORA2A (0.76) | ADORA2AADORA1ACHE | |
| SCHEMBL1450138 | 0.86 | ADORA2A (0.80) | ADORA2AADORA1 | |
| SCHEMBL1449841 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL1449474 | 0.84 | ADORA2A (0.72) | ADORA2AADORA1 | |
| SCHEMBL1449487 | 0.83 | ADORA2A (0.78) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | claimed |
| EP-2564871-B1 | Therapeutic Agent for Migraine | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-11-15 | — | — | EP | disclosed |
| EP-2308509-B1 | INHIBITOR OF ANALGESIC TOLERANCE | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9254283-B2 | Therapeutic agent for migraine | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-8865731-B2 | Inhibitor of analgesic tolerance | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-8865731-B2 | Inhibitor of analgesic tolerance | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| EP-2564871-A1 | Therapeutic Agent for Migraine | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110183992-A1 | THERAPEUTIC AGENT FOR MIGRAINE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20110183992-A1 | THERAPEUTIC AGENT FOR MIGRAINE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| EP-2322223-A1 | THERAPEUTIC AGENT FOR MIGRAINE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20110105465-A1 | INHIBITOR OF ANALGESIC TOLERANCE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105465-A1 | INHIBITOR OF ANALGESIC TOLERANCE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| WO-2006032273-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | ADORA2A, HTR2C, ADORA2B | ADORA2A 1/4885ADORA1 7/4885ACHE 1238/4885 |
| US-20110183992-A1 | THERAPEUTIC AGENT FOR MIGRAINE | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ACHE 314/4885 |
| US-20110105465-A1 | INHIBITOR OF ANALGESIC TOLERANCE | ADORA2A, OPRK1, OPRL1 | ADORA2A 1/4885ADORA1 6/4885ACHE 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.